[Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.]

[Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.] Arch Esp Urol. 2018 May;71(4):453-457 Authors: Chantada-Abal V, Chantada-Tirado C, Lamas-Díaz L, Caramés-Masana F, Villegas-Piguave AD, Villar-Vázquez N Abstract Bacilus Calmette-Guerin (BCG) administered intravesical is an effective therapy in non muscle invasive bladder cancer (NMIBC), but it presents limitations regarding recurrence and toxicity. For years, many case series have been published where sequential therapy with BCG and Mitomycin C (MMC) was tried. In this article, we perform a review of the data supplied by these articles with the aim to determine the safety and efficacy of combination, and what is the group of patients it should be indicated. Many studies show that combination therapy did not cause more toxicity and improved the interval free of disease with decrease of tumor progression compared to BCG or MMC monotherapy. Therefore, a combination of MMC and BCG therapy seems safe, but more clinical studies are required for a future evaluation. PMID: 29745935 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research